GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (XTER:YP1A) » Definitions » Other Gross PPE

Immutep (XTER:YP1A) Other Gross PPE : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Immutep Other Gross PPE?

Immutep's Other Gross PPE for the quarter that ended in Dec. 2023 was €0.00 Mil.

Immutep's quarterly Other Gross PPE increased from Jun. 2023 (€-0.00 Mil) to Sep. 2023 (€0.00 Mil) but then stayed the same from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Immutep's annual Other Gross PPE increased from Jun. 2021 (€0.00 Mil) to Jun. 2022 (€0.00 Mil) but then declined from Jun. 2022 (€0.00 Mil) to Jun. 2023 (€-0.00 Mil).


Immutep Other Gross PPE Historical Data

The historical data trend for Immutep's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Other Gross PPE Chart

Immutep Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immutep Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immutep Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Immutep (XTER:YP1A) Business Description

Traded in Other Exchanges
Address
264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (XTER:YP1A) Headlines

No Headlines